AbbVie Targets Hetero Over Generic Norvir Plans
According to AbbvVie, Hetero’s abbreviated new drug application for 100-milligram generic ritonavir infringes five patents covering Norvir — U.S. Patent Numbers 7,148,359; 7,364,752; 8,268,349; 6,037,157; and 6,703,403.
“AbbVie will be substantially and irreparably damaged and harmed by the infringing activities … unless those activities are precluded by this court,” the complaint said. “AbbVie does not have...
To view the full article, register now.